Dyadic International Inc (DYAI) stock
DYAINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$0.32+0.00 (+1.30%)
Close on Nov 18, 2026Market cap $11.66MP/E –Yield –
Dyadic International r&d expenses
Research and development expenses are spending on new products and technology.
Dyadic International's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.70M, down 24.3% year over year. For fiscal 2025 it was $2.15M, up 5.4% from the year before. The highest annual figure on record is $8.39M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.15M | +5.4% |
| FY2024 | Dec 31, 2024 | $2.04M | -38.0% |
| FY2023 | Dec 31, 2023 | $3.30M | -26.7% |
| FY2022 | Dec 31, 2022 | $4.50M | -46.4% |
| FY2021 | Dec 31, 2021 | $8.39M | +117.0% |
| FY2020 | Dec 31, 2020 | $3.87M | +25.3% |
| FY2019 | Dec 31, 2019 | $3.09M | +46.9% |
| FY2018 | Dec 31, 2018 | $2.10M | +19.0% |
| FY2017 | Dec 31, 2017 | $1.77M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $429.95K | -24.8% |
| Q2 FY2026 | Jun 30, 2026 | $332.62K | -47.2% |
| Q1 FY2026 | Mar 31, 2026 | $476.07K | -3.8% |
| Q4 FY2025 | Dec 31, 2025 | $458.44K | -16.0% |
| Q3 FY2025 | Sep 30, 2025 | $571.87K | +24.3% |
| Q2 FY2025 | Jun 30, 2025 | $629.38K | +22.1% |
| Q1 FY2025 | Mar 31, 2025 | $494.98K | -5.3% |
| Q4 FY2024 | Dec 31, 2024 | $545.66K | -36.0% |
| Q3 FY2024 | Sep 30, 2024 | $460.24K | -35.8% |
| Q2 FY2024 | Jun 30, 2024 | $515.63K | -43.8% |
| Q1 FY2024 | Mar 31, 2024 | $522.72K | -35.5% |
| Q4 FY2023 | Dec 31, 2023 | $852.80K | +46.0% |
| Q3 FY2023 | Sep 30, 2023 | $716.35K | -3.7% |
| Q2 FY2023 | Jun 30, 2023 | $917.55K | -49.9% |
| Q1 FY2023 | Mar 31, 2023 | $810.57K | -39.6% |
| Q4 FY2022 | Dec 31, 2022 | $584.12K | -76.4% |
| Q3 FY2022 | Sep 30, 2022 | $743.59K | -60.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.83M | -17.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.34M | -99.9% |
| Q4 FY2021 | Dec 31, 2021 | $2.47M | +144.8% |
| Q3 FY2021 | Sep 30, 2021 | $1.90M | +92.8% |
| Q2 FY2021 | Jun 30, 2021 | $2.21M | +97.9% |
| Q1 FY2021 | Mar 31, 2021 | $1.81B | +239239.6% |
| Q4 FY2020 | Dec 31, 2020 | $1.01M | +37.4% |
| Q3 FY2020 | Sep 30, 2020 | $986.05K | +17.2% |
| Q2 FY2020 | Jun 30, 2020 | $1.12M | +36.4% |
| Q1 FY2020 | Mar 31, 2020 | $755.45K | +9.1% |
| Q4 FY2019 | Dec 31, 2019 | $735.64K | +64.6% |
| Q3 FY2019 | Sep 30, 2019 | $841.34K | +76.5% |
| Q2 FY2019 | Jun 30, 2019 | $818.24K | +36.1% |
| Q1 FY2019 | Mar 31, 2019 | $692.37K | +20.0% |
| Q4 FY2018 | Dec 31, 2018 | $446.91K | – |
| Q3 FY2018 | Sep 30, 2018 | $476.63K | – |
| Q2 FY2018 | Jun 30, 2018 | $601.20K | – |
| Q1 FY2018 | Mar 31, 2018 | $576.88K | – |
See a number that looks wrong?